Analysts Set Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Price Target at $54.00

Key Points

• Arcturus Therapeutics Holdings Inc. has received a consensus rating of "Buy" from nine brokerages, with eight analysts recommending a buy and one a strong buy, reflecting positive sentiment about the company's prospects.
• The average twelve-month target price for Arcturus stock is $54.00, indicating potential growth from its current trading price of $12.21.
• Several hedge funds have significantly increased their stakes in the company, highlighting strong institutional interest and confidence in Arcturus' market position.

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) has been given an average rating of "Buy" by the nine brokerages that are currently covering the stock, Marketbeat.com reports. Eight equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $54.00.

ARCT has been the topic of a number of recent analyst reports. Wells Fargo & Company cut their price target on shares of Arcturus Therapeutics from $50.00 to $45.00 and set an "overweight" rating on the stock in a report on Wednesday, May 14th. Citigroup reissued a "buy" rating on shares of Arcturus Therapeutics in a research note on Tuesday, May 13th. Canaccord Genuity Group reduced their price target on Arcturus Therapeutics from $68.00 to $66.00 and set a "buy" rating on the stock in a report on Tuesday, May 13th. Scotiabank reaffirmed an "outperform" rating on shares of Arcturus Therapeutics in a research report on Wednesday, July 2nd. Finally, Wall Street Zen lowered Arcturus Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, July 5th.

Arcturus Therapeutics Trading Down 0.6%

ARCT stock traded down $0.07 during trading on Thursday, hitting $11.91. 396,324 shares of the company traded hands, compared to its average volume of 433,065. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.64 and a current ratio of 5.64. The company has a 50-day moving average of $13.15 and a 200-day moving average of $13.33. The firm has a market capitalization of $323.01 million, a PE ratio of -4.71 and a beta of 2.26. Arcturus Therapeutics has a 1 year low of $8.04 and a 1 year high of $25.88.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The biotechnology company reported ($0.52) earnings per share for the quarter, beating analysts' consensus estimates of ($1.58) by $1.06. Arcturus Therapeutics had a negative return on equity of 27.41% and a negative net margin of 47.47%. The firm had revenue of $29.38 million during the quarter, compared to analyst estimates of $25.64 million. Analysts predict that Arcturus Therapeutics will post -2.22 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC lifted its stake in shares of Arcturus Therapeutics by 6.4% in the 2nd quarter. Geode Capital Management LLC now owns 606,291 shares of the biotechnology company's stock valued at $7,889,000 after purchasing an additional 36,671 shares during the period. Corton Capital Inc. bought a new position in Arcturus Therapeutics in the second quarter worth $174,000. Spire Wealth Management lifted its position in Arcturus Therapeutics by 76.0% during the second quarter. Spire Wealth Management now owns 9,955 shares of the biotechnology company's stock valued at $130,000 after buying an additional 4,300 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its holdings in shares of Arcturus Therapeutics by 67.0% during the 2nd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 25,385 shares of the biotechnology company's stock valued at $330,000 after buying an additional 10,188 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd grew its position in shares of Arcturus Therapeutics by 92.5% in the 2nd quarter. Y Intercept Hong Kong Ltd now owns 44,432 shares of the biotechnology company's stock worth $578,000 after buying an additional 21,355 shares during the period. Hedge funds and other institutional investors own 94.54% of the company's stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.